Aktiesnakken — Februar 2010
-
15 fra placebo
-
There was a suspsicion of a drug related death....but it turned to be related to placebo
-
statistik for de 3 arme gennemgås... mht demografi. ser ret ens ud.
-
Primary endpoint: significant improvement of voluntary movements.
-
den lave dosisgruppe er ikke signifikant forskellig fra placebo
-
den høje dosis er derimod
-
det samme billede mht. doser når det kommer til "Motor function" (includes voluntary and involuntary movement)
-
div vurdering af symptomer gennemgås.
-
der var noget frygt mht. "chorea" (hvad det så er) men den viste sig ubegrundet
-
Safety profile:
-
Any adverse Events er lav ift.... ( i 60'erne %)
-
disse inkluderer alt.
-
over hele 6mdr perioden
-
afhængig af hvad man måler svarer forbedringen i "motor functions" til ca. 6-15 mdr (sygdomsforløb)
-
conclusion. Signifacantly improve motor functions
-
no "thearapeutic disadvantages"... (no worsening of disease ... and no increased adverse events)
-
Så er der Q&A.
-
Novod, handelsbanken:
-
any cross read to be made with HART-study i USA.... særligt 3 vs 6mdr?
-
og så et spgm om timing mht. filing m.m.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind